RPS6KA1 and melanoma: Pre-treatment of the NF-1LOF melanoma cell line MeWo and the BRAFMut MaMel51 with the RSK inhibitor PMD-026 could significantly enhance the activation of both gp100- and Melan-A-specific T cells as quantified by an increased IFNγ secretion (Fig. 5D).